For the First Time, Neurological Treatment for Type 3 Gaucher Includes Patients Weighing 15 kg or More
Key Facts
The U.S. Food and Drug Administration approved Invelbray, known scientifically as venglustat, on November 18, 2026, making it the first approved treatment for the neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg. The decision targets patients with involvement of the brain and nervous system, a feature that distinguishes type 3 from type 1. The agency’s acting commissioner, Kyle Diamantas, said the drug’s ability to cross the blood-brain barrier “means it can reach the source of the buildup that drives neurological symptoms.” The agency granted approval to Genzyme, a Sanofi subsidiary, after the drug received orphan-drug designation and priority review. The decision adds a treatment option targeting neurological symptoms to care for a rare disease whose symptoms may worsen over time.
Type 3 Gaucher disease affects the brain and nervous system, and its symptoms may include difficulties with balance, coordination, speech, memory and thinking. Invelbray works as an inhibitor of the enzyme glucosylceramide synthase and crosses the blood-brain barrier to reduce the buildup of harmful substances in the body and brain, according to the Food and Drug Administration. The pathway is significant because neurological symptoms remain part of the disease even after systemic manifestations have stabilized in some patients. Sanofi’s portfolio already includes Cerdelga for type 1 Gaucher disease and Cerezyme for symptoms outside the brain and nervous system in patients with types 1 and 3, Reuters reported. Invelbray therefore targets neurological symptoms that those treatments were not designed to address by reaching the brain.
The approval was based on the Phase 3 LEAP2MONO trial, which included 43 patients with type 3 Gaucher disease aged 12 years and older. Participants received oral Invelbray once daily or the enzyme replacement therapy imiglucerase intravenously every two weeks, and the comparison lasted 52 weeks. Patients had previously received enzyme replacement therapy and their systemic disease had stabilized before entering the trial. Sanofi said a composite test of several neurological measures showed Invelbray was statistically superior to imiglucerase, with a p-value of 0.0137. The analysis measured change from baseline through week 52 on a modified motor coordination scale and a neurocognitive assessment index, combining measures of movement and cognition in the evaluation of outcomes.
Data from the primary analysis period showed differences in some side effects between the two treatments: diarrhea was reported in 14% of Invelbray users versus 0% with imiglucerase, and nausea in 14% versus 5%. Sanofi also reported spleen enlargement in 14% versus 0% in the same data. Common side effects include gastrointestinal symptoms and effects on mood, according to the treatment information. The label carries warnings about suicidal thoughts and behavior, lens opacity in children and embryo-fetal toxicity. These warnings place known risks among the important information accompanying the approval, alongside the neurological results on which the decision was based.
In the stock market, Sanofi shares listed in New York under the ticker SNY closed at $47.12 on November 18, compared with a close of $47.53 on November 17. These prices do not establish when the approval announcement was issued during the trading session, so the share move cannot be attributed to the regulatory decision alone. Outside the United States, the drug was under regulatory review for type 3 Gaucher disease in the European Union, Japan and other markets. Sanofi said it aims to submit additional global regulatory applications during 2026 and 2027, while the open-label extension phase of the LEAP2MONO trial continues and its results will be presented when available. Completion of these reviews and the subsequent data represent the drug’s next steps following its U.S. approval.